BAYER Australia has responded
to a segment on a TV current
affairs program last week relating
to its YAZ and Yasmin combined
oral contraceptives, saying the
report “contained irresponsible and
inaccurate claims”.
Bayer medical director Jan
Twomey said there was no new
data on the risk-benefit profile of
the medications, despite the story
highlighting claimed increased risks
of venous thromboembolism.
“All combined oral contraceptives
carry risks, including an increased
risk of thromboembolism,” Twomey
said, adding that the risk had been
recognised for many years and
is outlined in both PI and CMIs
supplied to patients.
“We take the safety of our
medicines very seriously,” she said.The above article was sent to subscribers in Pharmacy Daily's issue from 08 May 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 May 13
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.